Drug Combinations to Preempt Resistance in AML


2020 Emerging Leader Award

Jeffrey Tyner, PhD, Oregon Health and Science University

Dr. Tyner is researching new drug combinations that can help avoid relapse in acute myeloid leukemia (AML) patients who have been treated with targeted therapeutic agents. Although response rates with targeted therapies are promising (ranging from 30% to 80%), most AML patients will relapse in less than one year. Researchers in the Tyner laboratory are using CRISPR/Cas9 genetic screens to uncover mechanisms of sensitivity or resistance to a panel of different drug combinations and to predict which combinations are most likely to have longer-lasting anti-cancer activity. Dr. Tyner attended Grinnell College and Washington University in St. Louis and is currently a Professor at the Knight Cancer Institute, Oregon Health & Science University. Dr. Tyner’s research is focused on drug combinations to enhance therapeutic efficacy and circumvent drug resistance.

published research

Zhang H, Nakauchi Y, Köhnke T, Stafford M, Bottomly D, Thomas R, Wilmot B, McWeeney SK, Majeti R, Tyner JW. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020.

Giacopelli B, Wang M, Cleary A, Wu YZ, Schultz AR, Schmutz M, Blachly JS, Eisfeld AK, Mundy-Bosse B, Vosberg S, Greif PA, Claus R, Bullinger L, Garzon R, Coombes KR, Bloomfield CD, Druker BJ, Tyner JW, Byrd JC, Oakes CC. DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. Genome Res. 2021.

BACK TO OUR PORTFOLIO